Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Cutler

Showing results (171-180 of 217) with videos related to

Pageof 22
Sort By:
Clinical Pharmacokinetics|April 28, 2020
Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) InhibitorDaryl J Fediuk, Gianluca Nucci, Vikas Kumar Dawra, et al.
Clinical Pharmacology in Drug Development|May 23, 2018
Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy SubjectsVikas Kumar Dawra, David L Cutler, Susan Zhou, et al.
European Journal of Clinical Pharmacology|February 9, 2012
Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal diseaseTeddy Kosoglou, Walter K Kraft, Bharath Kumar, et al.
FEBS Letters|June 24, 1991
Change in charge of an unvaried heme contact residue does not cause a major change of conformation in cytochrome cA G Thurgood, G J Pielak, R L Cutler, et al.
European Journal of Clinical Pharmacology|October 5, 2011
No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjectsTeddy Kosoglou, Larisa Reyderman, Claudia Kasserra, et al.
Cancer Chemotherapy and Pharmacology|October 26, 2010
Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumorsCarlos Castaneda, Kellen L Meadows, Roxanne Truax, et al.
Blood|April 15, 1997
Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemiaD Pajkrt, T van der Poll, M Levi, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 25, 2001
Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidaseN E Austin, S J Baldwin, L Cutler, et al.
The New England Journal of Medicine|February 10, 2021
Phase 3 Trials of Tirbanibulin Ointment for Actinic KeratosisAndrew Blauvelt, Steven Kempers, Edward Lain, et al.
The American Journal of Psychiatry|October 1, 1989
A basic residency curriculum concerning the chronically mentally illL R Faulkner, D L Cutler, D D Krohn, et al.
Pageof 22

Showing results (171-180 of 217) with videos related to

Sort By:
Pageof 22
Clinical Pharmacokinetics|April 28, 2020
Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) InhibitorDaryl J Fediuk, Gianluca Nucci, Vikas Kumar Dawra, et al.
Clinical Pharmacology in Drug Development|May 23, 2018
Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy SubjectsVikas Kumar Dawra, David L Cutler, Susan Zhou, et al.
European Journal of Clinical Pharmacology|February 9, 2012
Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal diseaseTeddy Kosoglou, Walter K Kraft, Bharath Kumar, et al.
FEBS Letters|June 24, 1991
Change in charge of an unvaried heme contact residue does not cause a major change of conformation in cytochrome cA G Thurgood, G J Pielak, R L Cutler, et al.
European Journal of Clinical Pharmacology|October 5, 2011
No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjectsTeddy Kosoglou, Larisa Reyderman, Claudia Kasserra, et al.
Cancer Chemotherapy and Pharmacology|October 26, 2010
Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumorsCarlos Castaneda, Kellen L Meadows, Roxanne Truax, et al.
Blood|April 15, 1997
Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemiaD Pajkrt, T van der Poll, M Levi, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 25, 2001
Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidaseN E Austin, S J Baldwin, L Cutler, et al.
The New England Journal of Medicine|February 10, 2021
Phase 3 Trials of Tirbanibulin Ointment for Actinic KeratosisAndrew Blauvelt, Steven Kempers, Edward Lain, et al.
The American Journal of Psychiatry|October 1, 1989
A basic residency curriculum concerning the chronically mentally illL R Faulkner, D L Cutler, D D Krohn, et al.
Pageof 22